U.S. biosimilar approvals poised to grow, but market uptake faces several challenges,
Biosimilar approvals in the U.S. are expected to increase during the next five years, but safety concerns among physicians and the need for greater regulatory clarity concerning therapeutic interchangeability could hinder market uptake, according to a study recently completed by Tufts. March 05, 2015